non-health resources utilization under routine medical practice derived in substantial costs when treating refractory painful due to cervical or lumbar radiculopathy. About two-thirds of the total costs were derived from non-health resources. OBJECTIVES: To analyze the Pregabalin (PGB) effect under routine medical practice on longitudinal health and non-health resources utilization (HRU) and derived costs of treating refractory painful Radiculopathy in Primary Care Setting (PCS) during 12-weeks. METHODS: A representative sample of PC centres included men and women above 18 years, with chronic pain (6-month or more) due to cervical (17%) or lumbar (83%) radiculopathy refractory to, at least, one previous analgesic [mean (SD) number of drugs; 2.6 (1.4)], in a prospective, naturalistic, 12-weeks two-visit study. Health resources included all-type medical visits, hospitalizations, complementary test and pharmacological and non-pharmacological therapies. Non-health included wages loses due to loss-work-days equivalents (LWDE = absenteeism days + days working with reduced productivity due to pain). Pain severity was measured by McGill-pain scale. Descriptive statistics and ANCOVA models were applied to compare 12-weeks periods of treatment. RESULTS: Onethousand-three-hundred-fifty-one PGB-naive patients [55.8% women, 56.7 (12.5) years] were analyzed: 490 (36%) switched to PGB as monotherapy (PGBm), 702 (52%) patients received PGB as add-on therapy (PGBadd-on), and in 159 (12%) previous treatment was replaced by a regimen not including PGB (Non-PGB). As compared to non-PGB, both PGBm and PGBadd-on showed significantly higher HRU reduction. The extra costs of drugs, particularly in PGB subgroups [€15.4 (39.1), €148.6 (109.1) and €145.3 (119.6), respectively (p < 0.0001 within and between groups)] was off-set by higher significant reductions in all other components of health costs (except non-pharmacological therapies in non-PGB group) yielding to a greater total cost reductions: €1203.3 (1805.6), €1423.2 (1650.0) and €1429.2 (1966.2), respectively (p < 0.001 within and p = 0.0004 between groups). CONCLUSION: In the primary care setting either add-on or monotherapy with pregabalin under routine medical practice was associated with a significant longitudinal reduction in HRU and total costs when compared with non-PGB therapy in subjects with painful radiculopathy of cervical or lumbar origin.
peripheral NeP followed in PCS under routine medical practice. METHODS: A 12-weeks cross-sectional and retrospective analysis was carried out in year 2006 in a whole-nation representative sample of PC centres. Men and women above 18 years, with chronic pain (6-month or more) due to peripheral NeP (diabetic neuropathy, post-herpetic neuralgia or trigeminal neuralgia), and refractory to, at least, one previous analgesic were included in the analysis. Health resources included all-type medical visits, hospitalizations, complementary test and pharmacological and nonpharmacological therapies. Non-health included wages loses due to loss-work-days equivalents (LWDE = absenteeism days + days working with reduced productivity due to pain). Pain severity was measured by McGill-pain scale. RESULTS: One-thousandfour-hundred-thirty-nine subjects [58.8% women, 59.5 (12.7) years] were analyzed: 783 (54%) with diabetic painful neuropathy (DPN), 486 (34%) with post-herpetic neuralgia (PHN), and 170 (12%) with trigeminal neuralgia (TN). Last-week mean pain severity was 70.8 (16.1) mm with 60.2% declaring the pain as severe or worst the day of collecting data. Previous mean (SD) number of drugs was 2.3 (1.3), with a 30.3% on one-drug only; 72% on NSAIDs, 43% on paracetamol, 36% on opiods, 23% on antiepileptics, and 11% on antidepressants. Quarterly mean LWDE was 37.5 (27.6) days. Medical visits average per trimester was 9.7 (7.6), with 4.4% declaring one-hospitalization. Quarterly total mean cost was €2689 (2236); €983 (1394) direct health cost and €1706 (1440) indirect cost. Cost and health resources utilization were not associated to aetiological cause of pain. CONCLUSION: In the primary care setting, health and non-health resources utilization under routine medical practice derived in substantial costs when treating the associated refractory pain to peripheral neuropathies due to diabetes, postherpetic or trigeminal neuralgia. Two-thirds of the total costs were derived from non-health resources.
participants missed a total of 191 work hours due to BTP (mean = 1.9 work hours lost per participant). Many were unable to work due to disability (n = 45; 31.7%) and disability was more common in patients with 2 or more painful conditions (p = 0.004). Anxiety and depression were noted to be prevalent (22.5% reported anxiety, 24.6% reported depression, 16.2% reported both), particularly among those with headache alone or 2 or more painful conditions (p = 0.035). CONCLUSION: Patients with BTP frequently seek care to control their pain and also experience productivity loss. Anxiety and depression may add to the economic burden of BTP.
PAIN-Health Care Use & Policy Studies

PPN8 CHRONIC PAIN TREATMENT WITH OPIOIDS: PRACTICE DOES NOT FOLLOW POLICY
Victor TW, Alvarez NA, Gould EM Endo Pharmaceuticals Inc, Chadds Ford, PA, USA OBJECTIVES: To examine the use of extended release (ER) opioids relative to immediate release (IR) opioids in chronic opioid treatment episodes. METHODS: Data from the i3 Innovus Lab/Rx Database were used in this analysis. Enrollees having at least one pharmacy claim for a combination opioid, extended release opioid or immediate release opioid between June-2003 and May-2006 and having at least one year of continuous enrollment beyond the date of their first observed opioid pharmacy claim were included in this analysis. Opioid-related treatment episodes were created by combining contiguous days of therapy allowing for a maximum of a 7-day gap between medication refills. Opioid-containing preparations were classified as either ER or IR formulations. Outcomes are reported in the form of probabilities and odds-ratios. RESULTS: A total of 3,993,011 opioid treatment episodes were derived from 1,967,898 patients. Overall, treatment episodes involving IR preparations (97.7%) are more prevalent than treatment episodes using ER preparations (2.3%). The odds of an ER preparation being prescribed chronically (> = 60 days) was approximately 11 times that of an IR preparation, OR = 10.7. The data were further stratified by prescriber-type (designated as pain specialist or non-specialist). The probability of a pain specialist prescribing ER opioids in these chronic episodes was 19.1%; whereas the probability for non-specialists was 13.7%. In comparing the two prescriber groups, pain specialists are about 50% more likely to prescribe ER opioids relative to nonspecialists, OR = 1.49. CONCLUSION: These data suggest that clinical practice does not follow accepted pain treatment guidelines for chronic pain. Further research will need to be conducted to better understand physician prescribing behaviors as they relate to chronic pain treatment and why the existence of treatment guidelines may not alone be sufficient to promote a medication regimen that will optimize pain care for appropriate patients.
PAIN-Methods and Concepts
PPN9 PERCEPTION OF BREAKTHROUGH PAIN IN PATIENTS WITH CHRONIC PAINFUL CONDITIONS
Pizzi LT 1 , Lee SP 1 , Richardson D 1 , Cobb N 2 , Leas B 2 , Toner R 2 , Pracilio V 2 , Ballas S 2 , Ashkenazi A 2 , Derk CT 2 , Wang D 2 , DeSousa E 2 1 Jefferson Medical College, Philadelphia, PA, USA, 2 The Breakthrough Pain Study Group, Philadelphia, PA, USA OBJECTIVES: To understand how patients with chronic noncancer pain define and describe breakthrough pain (BTP).
